The potential role of Aurora kinase inhibitors in haematological malignancies

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Aurora kinases play an important role in the control of the cell cycle and have been implicated in tumourigenesis in a number of cancers. Among the haematological malignancies, overexpression of Aurora kinases has been reported in acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia, multiple myeloma, aggressive non-Hodgkin lymphoma and Hodgkin lymphoma. A large number of Aurora kinase inhibitors are currently in different stages of clinical development. In addition to varying in their selectivity for the different Aurora kinases, some also have activity directed at other cellular kinases involved in important molecular pathways in cancer cells. This review summarizes the biology of Aurora kinases and discusses why they may be good therapeutic targets in different haematological cancers. We describe preclinical data that has served as the rationale for investigating Aurora kinase inhibitors in different haematological malignancies, and summarize published results from early phase clinical trials. While the anti-tumour effects of Aurora kinase inhibitors appear promising, we highlight important issues for future clinical research and suggest that the optimal use of these inhibitors is likely to be in combination with cytotoxic agents already in use for the treatment of various haematological cancers.

Original languageEnglish
Pages (from-to)561-579
Number of pages19
JournalBritish Journal of Haematology
Volume155
Issue number5
DOIs
StatePublished - Dec 2011

Fingerprint

Aurora Kinases
Hematologic Neoplasms
Neoplasms
Cytotoxins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell Cycle Checkpoints
Multiple Myeloma
Hodgkin Disease
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Phosphotransferases
Clinical Trials

Keywords

  • Cell cycle
  • Lymphoma
  • Myeloid leukaemia
  • Myeloma

ASJC Scopus subject areas

  • Hematology

Cite this

The potential role of Aurora kinase inhibitors in haematological malignancies. / Farag, Sherif.

In: British Journal of Haematology, Vol. 155, No. 5, 12.2011, p. 561-579.

Research output: Contribution to journalArticle

@article{3cbc4eb34255425e908fe00a3000378c,
title = "The potential role of Aurora kinase inhibitors in haematological malignancies",
abstract = "Aurora kinases play an important role in the control of the cell cycle and have been implicated in tumourigenesis in a number of cancers. Among the haematological malignancies, overexpression of Aurora kinases has been reported in acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia, multiple myeloma, aggressive non-Hodgkin lymphoma and Hodgkin lymphoma. A large number of Aurora kinase inhibitors are currently in different stages of clinical development. In addition to varying in their selectivity for the different Aurora kinases, some also have activity directed at other cellular kinases involved in important molecular pathways in cancer cells. This review summarizes the biology of Aurora kinases and discusses why they may be good therapeutic targets in different haematological cancers. We describe preclinical data that has served as the rationale for investigating Aurora kinase inhibitors in different haematological malignancies, and summarize published results from early phase clinical trials. While the anti-tumour effects of Aurora kinase inhibitors appear promising, we highlight important issues for future clinical research and suggest that the optimal use of these inhibitors is likely to be in combination with cytotoxic agents already in use for the treatment of various haematological cancers.",
keywords = "Cell cycle, Lymphoma, Myeloid leukaemia, Myeloma",
author = "Sherif Farag",
year = "2011",
month = "12",
doi = "10.1111/j.1365-2141.2011.08898.x",
language = "English",
volume = "155",
pages = "561--579",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The potential role of Aurora kinase inhibitors in haematological malignancies

AU - Farag, Sherif

PY - 2011/12

Y1 - 2011/12

N2 - Aurora kinases play an important role in the control of the cell cycle and have been implicated in tumourigenesis in a number of cancers. Among the haematological malignancies, overexpression of Aurora kinases has been reported in acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia, multiple myeloma, aggressive non-Hodgkin lymphoma and Hodgkin lymphoma. A large number of Aurora kinase inhibitors are currently in different stages of clinical development. In addition to varying in their selectivity for the different Aurora kinases, some also have activity directed at other cellular kinases involved in important molecular pathways in cancer cells. This review summarizes the biology of Aurora kinases and discusses why they may be good therapeutic targets in different haematological cancers. We describe preclinical data that has served as the rationale for investigating Aurora kinase inhibitors in different haematological malignancies, and summarize published results from early phase clinical trials. While the anti-tumour effects of Aurora kinase inhibitors appear promising, we highlight important issues for future clinical research and suggest that the optimal use of these inhibitors is likely to be in combination with cytotoxic agents already in use for the treatment of various haematological cancers.

AB - Aurora kinases play an important role in the control of the cell cycle and have been implicated in tumourigenesis in a number of cancers. Among the haematological malignancies, overexpression of Aurora kinases has been reported in acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia, multiple myeloma, aggressive non-Hodgkin lymphoma and Hodgkin lymphoma. A large number of Aurora kinase inhibitors are currently in different stages of clinical development. In addition to varying in their selectivity for the different Aurora kinases, some also have activity directed at other cellular kinases involved in important molecular pathways in cancer cells. This review summarizes the biology of Aurora kinases and discusses why they may be good therapeutic targets in different haematological cancers. We describe preclinical data that has served as the rationale for investigating Aurora kinase inhibitors in different haematological malignancies, and summarize published results from early phase clinical trials. While the anti-tumour effects of Aurora kinase inhibitors appear promising, we highlight important issues for future clinical research and suggest that the optimal use of these inhibitors is likely to be in combination with cytotoxic agents already in use for the treatment of various haematological cancers.

KW - Cell cycle

KW - Lymphoma

KW - Myeloid leukaemia

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=81155155493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155155493&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08898.x

DO - 10.1111/j.1365-2141.2011.08898.x

M3 - Article

VL - 155

SP - 561

EP - 579

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -